Overview

Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the effects of 16-week treatment with DFD-29 40 mg QD dose in comparison to Placebo on the skin, intestinal and vaginal microbiota.
Phase:
Phase 1
Details
Lead Sponsor:
Journey Medical Corporation
Collaborator:
Dr. Reddy's Laboratories Limited
Treatments:
Minocycline